Vihren Kolev
Research Subjects
Research Interests
Vihren Kolev has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Adnan O. Abu-Yousif
Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
9 shared publications Atsushi Matsuda
9 shared publicationsChris Gemski
9 shared publicationsChristopher Arendt
9 shared publicationsDoanh Mai
9 shared publicationsElizabeth Carideo Cunniff
9 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods SM1 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary methods and results: The supplementary methods describe: 1) the chemical synthesis and characterization of TAK-676, inclusive of TAK-676 chemical structure, purification chromatogram and NMR characterization; 2) details regarding STING DNA cloning and purification (recombinant E. coli expression utilizing an N-terminal His tag and C-terminal Avi tag) for STING binding assays (time-resolved fluorescence resonance energy transfer assay); 3) description of pathway activation assays (inclusive of cell culture methods) in THP1-Dual™, CT26.WT, HEK293T (lack endogenous STING expression), and RAW-Lucia™ ISG cell lines; 4) methods describing the generation of STING knockout and WT cell line clones in CT26.WT and BF1610 cells via the CRISPR method; 5) details of immune cell activation assays in human dendritic cells, mouse dendritic cells, NK cells and T cells analyzed by flow cytometry; 6) details regarding inoculation of BALB/C mice with A20 cells (for generation of A20 syngeneic tumors) for pharmacokinetic analysis of TAK-676 administered intravenously; 7) details regarding inoculation of BALB/C (and Goldenticket mice with BF1610 tumor cells only) mice with CT26.WT, A20, and B16F10 tumor cells for in vivo antitumor activity analysis; 8) methods describing the in vivo pharmacodynamic effects of TAK-676 by cytokine induction and immune cell activation and proliferation. The supplementary results show that TAK-676 is tolerated in syngeneic mouse models supported by Supplementary Figure 3 (percentage body weight change in BALB/C mice [CT26.WT and A20 syngeneic tumors]) and Supplementary Figure 4 (percentage body weight change in STING-deficient Goldenticket mice [STING WT and B16F10 syngeneic tumors]).
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods SM1 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary methods and results: The supplementary methods describe: 1) the chemical synthesis and characterization of TAK-676, inclusive of TAK-676 chemical structure, purification chromatogram and NMR characterization; 2) details regarding STING DNA cloning and purification (recombinant E. coli expression utilizing an N-terminal His tag and C-terminal Avi tag) for STING binding assays (time-resolved fluorescence resonance energy transfer assay); 3) description of pathway activation assays (inclusive of cell culture methods) in THP1-Dual™, CT26.WT, HEK293T (lack endogenous STING expression), and RAW-Lucia™ ISG cell lines; 4) methods describing the generation of STING knockout and WT cell line clones in CT26.WT and BF1610 cells via the CRISPR method; 5) details of immune cell activation assays in human dendritic cells, mouse dendritic cells, NK cells and T cells analyzed by flow cytometry; 6) details regarding inoculation of BALB/C mice with A20 cells (for generation of A20 syngeneic tumors) for pharmacokinetic analysis of TAK-676 administered intravenously; 7) details regarding inoculation of BALB/C (and Goldenticket mice with BF1610 tumor cells only) mice with CT26.WT, A20, and B16F10 tumor cells for in vivo antitumor activity analysis; 8) methods describing the in vivo pharmacodynamic effects of TAK-676 by cytokine induction and immune cell activation and proliferation. The supplementary results show that TAK-676 is tolerated in syngeneic mouse models supported by Supplementary Figure 3 (percentage body weight change in BALB/C mice [CT26.WT and A20 syngeneic tumors]) and Supplementary Figure 4 (percentage body weight change in STING-deficient Goldenticket mice [STING WT and B16F10 syngeneic tumors]).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S5 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary figures: Supplementary Figure 1 shows cell viability of human monocyte-derived dendric cells and mouse bone marrow dendritic cells. Supplementary Figure 2 shows mean plasma and tumor concentration-time curves of TAK-676 in BALB/C mice (A20 syngeneic tumors). Supplementary Figure 3 shows percentage body weight change in BALB/C mice (CT26.WT and A20 syngeneic tumors). Supplementary Figure 4 shows percentage body weight change in STING-deficient Goldenticket mice (STING WT and B16F10 syngeneic tumors). Supplementary Figure 5 shows cytokine expression in A20 tumor-bearing mice (plasma and tumor).
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S5 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary figures: Supplementary Figure 1 shows cell viability of human monocyte-derived dendric cells and mouse bone marrow dendritic cells. Supplementary Figure 2 shows mean plasma and tumor concentration-time curves of TAK-676 in BALB/C mice (A20 syngeneic tumors). Supplementary Figure 3 shows percentage body weight change in BALB/C mice (CT26.WT and A20 syngeneic tumors). Supplementary Figure 4 shows percentage body weight change in STING-deficient Goldenticket mice (STING WT and B16F10 syngeneic tumors). Supplementary Figure 5 shows cytokine expression in A20 tumor-bearing mice (plasma and tumor).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S3 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary tables: Supplementary Table 1 describes where cells were obtained from and details of authentication and mycoplasma testing dates. Supplementary Table 2 shows TAK-676 potency in cynomolgus monkey, human, mouse, and rat STING via time-resolved fluorescence resonance energy transfer assay. Supplementary Table 3 shows pharmacokinetic parameters (Cmax and AUC) after TAK-676 administration in BALB/C mice (A20 tumors).
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S3 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary tables: Supplementary Table 1 describes where cells were obtained from and details of authentication and mycoplasma testing dates. Supplementary Table 2 shows TAK-676 potency in cynomolgus monkey, human, mouse, and rat STING via time-resolved fluorescence resonance energy transfer assay. Supplementary Table 3 shows pharmacokinetic parameters (Cmax and AUC) after TAK-676 administration in BALB/C mice (A20 tumors).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods SM1 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary methods and results: The supplementary methods describe: 1) the chemical synthesis and characterization of TAK-676, inclusive of TAK-676 chemical structure, purification chromatogram and NMR characterization; 2) details regarding STING DNA cloning and purification (recombinant E. coli expression utilizing an N-terminal His tag and C-terminal Avi tag) for STING binding assays (time-resolved fluorescence resonance energy transfer assay); 3) description of pathway activation assays (inclusive of cell culture methods) in THP1-Dual™, CT26.WT, HEK293T (lack endogenous STING expression), and RAW-Lucia™ ISG cell lines; 4) methods describing the generation of STING knockout and WT cell line clones in CT26.WT and BF1610 cells via the CRISPR method; 5) details of immune cell activation assays in human dendritic cells, mouse dendritic cells, NK cells and T cells analyzed by flow cytometry; 6) details regarding inoculation of BALB/C mice with A20 cells (for generation of A20 syngeneic tumors) for pharmacokinetic analysis of TAK-676 administered intravenously; 7) details regarding inoculation of BALB/C (and Goldenticket mice with BF1610 tumor cells only) mice with CT26.WT, A20, and B16F10 tumor cells for in vivo antitumor activity analysis; 8) methods describing the in vivo pharmacodynamic effects of TAK-676 by cytokine induction and immune cell activation and proliferation. The supplementary results show that TAK-676 is tolerated in syngeneic mouse models supported by Supplementary Figure 3 (percentage body weight change in BALB/C mice [CT26.WT and A20 syngeneic tumors]) and Supplementary Figure 4 (percentage body weight change in STING-deficient Goldenticket mice [STING WT and B16F10 syngeneic tumors]).
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods SM1 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary methods and results: The supplementary methods describe: 1) the chemical synthesis and characterization of TAK-676, inclusive of TAK-676 chemical structure, purification chromatogram and NMR characterization; 2) details regarding STING DNA cloning and purification (recombinant E. coli expression utilizing an N-terminal His tag and C-terminal Avi tag) for STING binding assays (time-resolved fluorescence resonance energy transfer assay); 3) description of pathway activation assays (inclusive of cell culture methods) in THP1-Dual™, CT26.WT, HEK293T (lack endogenous STING expression), and RAW-Lucia™ ISG cell lines; 4) methods describing the generation of STING knockout and WT cell line clones in CT26.WT and BF1610 cells via the CRISPR method; 5) details of immune cell activation assays in human dendritic cells, mouse dendritic cells, NK cells and T cells analyzed by flow cytometry; 6) details regarding inoculation of BALB/C mice with A20 cells (for generation of A20 syngeneic tumors) for pharmacokinetic analysis of TAK-676 administered intravenously; 7) details regarding inoculation of BALB/C (and Goldenticket mice with BF1610 tumor cells only) mice with CT26.WT, A20, and B16F10 tumor cells for in vivo antitumor activity analysis; 8) methods describing the in vivo pharmacodynamic effects of TAK-676 by cytokine induction and immune cell activation and proliferation. The supplementary results show that TAK-676 is tolerated in syngeneic mouse models supported by Supplementary Figure 3 (percentage body weight change in BALB/C mice [CT26.WT and A20 syngeneic tumors]) and Supplementary Figure 4 (percentage body weight change in STING-deficient Goldenticket mice [STING WT and B16F10 syngeneic tumors]).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in a suppressive tumor microenvironment (TME) remains a significant problem. New therapies that activate an innate immune response and relieve this suppression may be beneficial to overcome this hurdle. TAK-676 is a synthetic novel stimulator of interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate that TAK-676 dose-dependently triggers activation of the STING signaling pathway and activation of type I interferons. Furthermore, we show that TAK-676 is a highly potent modulator of both the innate and adaptive immune system and that it promotes the activation of dendritic cells, natural killer cells, and T cells in preclinical models. In syngeneic murine tumor models in vivo, TAK-676 induces dose-dependent cytokine responses and increases the activation and proliferation of immune cells within the TME and tumor-associated lymphoid tissue. We also demonstrate that TAK-676 dosing results in significant STING-dependent antitumor activity, including complete regressions and durable memory T-cell immunity. We show that TAK-676 is well tolerated, exhibits dose-proportional pharmacokinetics in plasma, and exhibits higher exposure in tumor. The intravenous administration of TAK-676 provides potential treatment benefit in a broad range of tumor types. Further study of TAK-676 in first-in-human phase I trials is ongoing.Significance:TAK-676 is a novel systemic STING agonist demonstrating robust activation of innate and adaptive immune activity resulting in durable antitumor responses within multiple syngeneic tumor models. Clinical investigation of TAK-676 is ongoing.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in a suppressive tumor microenvironment (TME) remains a significant problem. New therapies that activate an innate immune response and relieve this suppression may be beneficial to overcome this hurdle. TAK-676 is a synthetic novel stimulator of interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate that TAK-676 dose-dependently triggers activation of the STING signaling pathway and activation of type I interferons. Furthermore, we show that TAK-676 is a highly potent modulator of both the innate and adaptive immune system and that it promotes the activation of dendritic cells, natural killer cells, and T cells in preclinical models. In syngeneic murine tumor models in vivo, TAK-676 induces dose-dependent cytokine responses and increases the activation and proliferation of immune cells within the TME and tumor-associated lymphoid tissue. We also demonstrate that TAK-676 dosing results in significant STING-dependent antitumor activity, including complete regressions and durable memory T-cell immunity. We show that TAK-676 is well tolerated, exhibits dose-proportional pharmacokinetics in plasma, and exhibits higher exposure in tumor. The intravenous administration of TAK-676 provides potential treatment benefit in a broad range of tumor types. Further study of TAK-676 in first-in-human phase I trials is ongoing.Significance:TAK-676 is a novel systemic STING agonist demonstrating robust activation of innate and adaptive immune activity resulting in durable antitumor responses within multiple syngeneic tumor models. Clinical investigation of TAK-676 is ongoing.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S3 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary tables: Supplementary Table 1 describes where cells were obtained from and details of authentication and mycoplasma testing dates. Supplementary Table 2 shows TAK-676 potency in cynomolgus monkey, human, mouse, and rat STING via time-resolved fluorescence resonance energy transfer assay. Supplementary Table 3 shows pharmacokinetic parameters (Cmax and AUC) after TAK-676 administration in BALB/C mice (A20 tumors).
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S3 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary tables: Supplementary Table 1 describes where cells were obtained from and details of authentication and mycoplasma testing dates. Supplementary Table 2 shows TAK-676 potency in cynomolgus monkey, human, mouse, and rat STING via time-resolved fluorescence resonance energy transfer assay. Supplementary Table 3 shows pharmacokinetic parameters (Cmax and AUC) after TAK-676 administration in BALB/C mice (A20 tumors).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S5 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary figures: Supplementary Figure 1 shows cell viability of human monocyte-derived dendric cells and mouse bone marrow dendritic cells. Supplementary Figure 2 shows mean plasma and tumor concentration-time curves of TAK-676 in BALB/C mice (A20 syngeneic tumors). Supplementary Figure 3 shows percentage body weight change in BALB/C mice (CT26.WT and A20 syngeneic tumors). Supplementary Figure 4 shows percentage body weight change in STING-deficient Goldenticket mice (STING WT and B16F10 syngeneic tumors). Supplementary Figure 5 shows cytokine expression in A20 tumor-bearing mice (plasma and tumor).
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S5 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary figures: Supplementary Figure 1 shows cell viability of human monocyte-derived dendric cells and mouse bone marrow dendritic cells. Supplementary Figure 2 shows mean plasma and tumor concentration-time curves of TAK-676 in BALB/C mice (A20 syngeneic tumors). Supplementary Figure 3 shows percentage body weight change in BALB/C mice (CT26.WT and A20 syngeneic tumors). Supplementary Figure 4 shows percentage body weight change in STING-deficient Goldenticket mice (STING WT and B16F10 syngeneic tumors). Supplementary Figure 5 shows cytokine expression in A20 tumor-bearing mice (plasma and tumor).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in a suppressive tumor microenvironment (TME) remains a significant problem. New therapies that activate an innate immune response and relieve this suppression may be beneficial to overcome this hurdle. TAK-676 is a synthetic novel stimulator of interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate that TAK-676 dose-dependently triggers activation of the STING signaling pathway and activation of type I interferons. Furthermore, we show that TAK-676 is a highly potent modulator of both the innate and adaptive immune system and that it promotes the activation of dendritic cells, natural killer cells, and T cells in preclinical models. In syngeneic murine tumor models in vivo, TAK-676 induces dose-dependent cytokine responses and increases the activation and proliferation of immune cells within the TME and tumor-associated lymphoid tissue. We also demonstrate that TAK-676 dosing results in significant STING-dependent antitumor activity, including complete regressions and durable memory T-cell immunity. We show that TAK-676 is well tolerated, exhibits dose-proportional pharmacokinetics in plasma, and exhibits higher exposure in tumor. The intravenous administration of TAK-676 provides potential treatment benefit in a broad range of tumor types. Further study of TAK-676 in first-in-human phase I trials is ongoing.Significance:TAK-676 is a novel systemic STING agonist demonstrating robust activation of innate and adaptive immune activity resulting in durable antitumor responses within multiple syngeneic tumor models. Clinical investigation of TAK-676 is ongoing.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in a suppressive tumor microenvironment (TME) remains a significant problem. New therapies that activate an innate immune response and relieve this suppression may be beneficial to overcome this hurdle. TAK-676 is a synthetic novel stimulator of interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate that TAK-676 dose-dependently triggers activation of the STING signaling pathway and activation of type I interferons. Furthermore, we show that TAK-676 is a highly potent modulator of both the innate and adaptive immune system and that it promotes the activation of dendritic cells, natural killer cells, and T cells in preclinical models. In syngeneic murine tumor models in vivo, TAK-676 induces dose-dependent cytokine responses and increases the activation and proliferation of immune cells within the TME and tumor-associated lymphoid tissue. We also demonstrate that TAK-676 dosing results in significant STING-dependent antitumor activity, including complete regressions and durable memory T-cell immunity. We show that TAK-676 is well tolerated, exhibits dose-proportional pharmacokinetics in plasma, and exhibits higher exposure in tumor. The intravenous administration of TAK-676 provides potential treatment benefit in a broad range of tumor types. Further study of TAK-676 in first-in-human phase I trials is ongoing.Significance:TAK-676 is a novel systemic STING agonist demonstrating robust activation of innate and adaptive immune activity resulting in durable antitumor responses within multiple syngeneic tumor models. Clinical investigation of TAK-676 is ongoing.
- Open Access
- 23 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 2 (6) , 489-502
TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in a suppressive tumor microenvironment (TME) remains a significant problem. New therapies that activate an innate immune response and relieve this suppression may be beneficial to overcome this hurdle. TAK-676 is a synthetic novel stimulator of interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate that TAK-676 dose-dependently triggers activation of the STING signaling pathway and activation of type I interferons. Furthermore, we show that TAK-676 is a highly potent modulator of both the innate and adaptive immune system and that it promotes the activation of dendritic cells, natural killer cells, and T cells in preclinical models. In syngeneic murine tumor models in vivo, TAK-676 induces dose-dependent cytokine responses and increases the activation and proliferation of immune cells within the TME and tumor-associated lymphoid tissue. We also demonstrate that TAK-676 dosing results in significant STING-dependent antitumor activity, including complete regressions and durable memory T-cell immunity. We show that TAK-676 is well tolerated, exhibits dose-proportional pharmacokinetics in plasma, and exhibits higher exposure in tumor. The intravenous administration of TAK-676 provides potential treatment benefit in a broad range of tumor types. Further study of TAK-676 in first-in-human phase I trials is ongoing.Significance: TAK-676 is a novel systemic STING agonist demonstrating robust activation of innate and adaptive immune activity resulting in durable antitumor responses within multiple syngeneic tumor models. Clinical investigation of TAK-676 is ongoing.
- 23 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 2 (6) , 489-502
Open AccessTAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in a suppressive tumor microenvironment (TME) remains a significant problem. New therapies that activate an innate immune response and relieve this suppression may be beneficial to overcome this hurdle. TAK-676 is a synthetic novel stimulator of interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate that TAK-676 dose-dependently triggers activation of the STING signaling pathway and activation of type I interferons. Furthermore, we show that TAK-676 is a highly potent modulator of both the innate and adaptive immune system and that it promotes the activation of dendritic cells, natural killer cells, and T cells in preclinical models. In syngeneic murine tumor models in vivo, TAK-676 induces dose-dependent cytokine responses and increases the activation and proliferation of immune cells within the TME and tumor-associated lymphoid tissue. We also demonstrate that TAK-676 dosing results in significant STING-dependent antitumor activity, including complete regressions and durable memory T-cell immunity. We show that TAK-676 is well tolerated, exhibits dose-proportional pharmacokinetics in plasma, and exhibits higher exposure in tumor. The intravenous administration of TAK-676 provides potential treatment benefit in a broad range of tumor types. Further study of TAK-676 in first-in-human phase I trials is ongoing.Significance: TAK-676 is a novel systemic STING agonist demonstrating robust activation of innate and adaptive immune activity resulting in durable antitumor responses within multiple syngeneic tumor models. Clinical investigation of TAK-676 is ongoing.